Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
259 participants
INTERVENTIONAL
2010-05-31
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
QAX576
QAX576
QAX576
every 3 weeks via intravenous infusion
Placebo
Placebo
Placebo
every 3 weeks via intravenous infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QAX576
every 3 weeks via intravenous infusion
Placebo
every 3 weeks via intravenous infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female patients must be surgically sterilized or postmenopausal
* Male patients must use two forms of contraception
* Body mass index must be between 18 and 39 kg/m2
* Diagnosis of asthma for at least one year, which is not adequately controlled by inhaled corticosteroids and long acting beta-2 agonists
Exclusion Criteria
* Patients with a diagnosis of chronic obstructive pulmonary disease (COPD)
* Patients who have experienced a severe asthma attack/exacerbation requiring systemic corticosteroids or an increase in maintenance doses, within 6 weeks of screening
* Patients who have had a respiratory tract infection within 6 weeks prior to screening
* History of schistosomiasis, within 6 months of screening, or traveling to a country endemic with schistosomiasis within 6 months of completing the study
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Phoenix, Arizona, United States
Novartis Investigative Site
Huntington Beach, California, United States
Novartis Investigative Site
Owensboro, Kentucky, United States
Novartis Investigative Site
Wheaton, Maryland, United States
Novartis Investigative Site
Minneapolis, Minnesota, United States
Novartis Investigative Site
St Louis, Missouri, United States
Novartis Investigative Site
Las Vegas, Nevada, United States
Novartis Investigative Site
Marion, Ohio, United States
Novartis Investigative Site
Charleston, South Carolina, United States
Novartis Investigative Site
Summerville, South Carolina, United States
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Buenos Aires, , Argentina
Novartis Investigative Site
Mendoza, , Argentina
Novartis Investigative Site
Santa Fe, , Argentina
Novartis Investigative Site
Brussels, , Belgium
Novartis Investigative Site
Eupen, , Belgium
Novartis Investigative Site
Ghent, , Belgium
Novartis Investigative Site
Laken, , Belgium
Novartis Investigative Site
Leuven, , Belgium
Novartis Investigative Site
Liège, , Belgium
Novartis Investigative Site
Rokycany, Czech Republic, Czechia
Novartis Investigative Site
Strakonice, Czech Republic, Czechia
Novartis Investigative Site
Teplice, CZE, Czechia
Novartis Investigative Site
Tábor, , Czechia
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Frankfurt, , Germany
Novartis Investigative Site
Großhansdorf, , Germany
Novartis Investigative Site
Kassel, , Germany
Novartis Investigative Site
Leipzig, , Germany
Novartis Investigative Site
Leipzig, , Germany
Novartis Investigative Site
Mainz, , Germany
Novartis Investigative Site
Rüdersdorf, , Germany
Novartis Investigative Site
Bialystok, , Poland
Novartis Investigative Site
Gdansk, , Poland
Novartis Investigative Site
Lodz, , Poland
Novartis Investigative Site
Lublin, , Poland
Novartis Investigative Site
Poznan, , Poland
Novartis Investigative Site
Kazan', Tatarstan Republic, Russia
Novartis Investigative Site
Barnaul, , Russia
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Nizhny Novgorod, , Russia
Novartis Investigative Site
Ryazan, , Russia
Novartis Investigative Site
Samara, , Russia
Novartis Investigative Site
Yaroslavl, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CQAX576A2207 from Novartis Clinical Trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-011590-32
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CQAX576A2207
Identifier Type: -
Identifier Source: org_study_id